IBIO

iBio, Inc. NASDAQ Listed Aug 19, 2008

Healthcare ·Biotechnology ·US · ibioinc.com

$1.59

-1.85% vs $1.62

Mkt Cap $25.1M

52w Low $0.56 31.6% of range 52w High $3.82

50d MA $1.75 200d MA $1.74

P/E (TTM) —

EV/EBITDA —

P/B 1.1x

Debt/Equity 0.2x

ROE -40.7%

P/FCF -1.1x

RSI (14) 27.60

ATR (14) $0.13

Beta 1.36

50d MA $1.75

200d MA $1.74

Avg Volume 793.3K

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

SIC Code

2834

CIK (SEC)

1420720

Phone

979 446 0027

8800 HSC Parkway · Bryan, TX 77807 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 10, 2026	AMC	-0.08	-0.09	-12.5%	2.27	+2.2%	-2.6%	-4.5%	+5.2%	+3.2%	+1.7%	—
Nov 12, 2025	AMC	-0.07	-0.11	-57.1%	1.25	-0.8%	-8.0%	+0.9%	-5.2%	+10.0%	-9.9%	—
Sep 5, 2025	AMC	-0.39	-0.31	+20.5%	0.83	-0.8%	+2.4%	-2.6%	+6.0%	+9.1%	-3.1%	—
May 2, 2025	AMC	-0.39	-0.49	-25.6%	1.01	+7.9%	-3.0%	-13.3%	+0.0%	-2.4%	-7.2%	—
Feb 10, 2025	AMC	-0.45	-0.48	-6.7%	3.42	-5.0%	-7.3%	+16.1%	-2.2%	-4.7%	+7.3%	—
Nov 12, 2024	AMC	-0.46	-0.46	+0.0%	2.55	+0.0%	-9.0%	-7.3%	+6.0%	-4.4%	+2.3%	—
Sep 25, 2024	AMC	-0.47	-0.91	-93.6%	1.82	+3.8%	+7.1%	+6.7%	+6.7%	+4.5%	-3.9%	—
May 13, 2024	AMC	—	-0.71	—	1.82	-0.5%	+3.3%	+0.0%	-3.7%	+9.4%	+8.6%	—
Feb 9, 2024	AMC	—	-2.42	—	1.18	-1.7%	+2.5%	+0.8%	-0.8%	+0.8%	+3.3%	—
Nov 14, 2023	AMC	—	-4.20	—	5.60	+0.0%	+0.0%	-3.6%	-3.7%	+0.0%	+3.8%	—
Sep 27, 2023	AMC	-0.41	0.26	+163.4%	5.80	+0.0%	+0.0%	+3.4%	+3.3%	-3.2%	-6.7%	—
May 11, 2023	AMC	-3.42	-6.61	-93.4%	20.20	+0.0%	+0.0%	-6.9%	-1.1%	+3.2%	-1.0%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jun 8	Raymond James	Initiates	Outperform	$5	$1.82	$1.87	+2.7%	-4.9%	-1.7%	+0.0%	-1.8%	+1.2%
Jun 5	B. Riley Securities	Initiates	Buy	$6	$1.93	$1.93	+0.0%	-5.7%	-4.9%	-1.7%	+0.0%	-1.8%
Apr 9	Chardan Capital	Maintains	Buy → Buy	—	$2.24	$2.23	-0.4%	-1.8%	-1.8%	+1.9%	-0.5%	-4.1%
Mar 18	Chardan Capital	Maintains	Buy → Buy	—	$2.46	$2.49	+1.2%	-11.0%	-4.1%	-0.5%	+5.7%	-5.9%
Feb 12	Chardan Capital	Maintains	Buy → Buy	—	$2.21	$2.20	-0.5%	-4.5%	+5.2%	+3.2%	+1.7%	+5.2%
Jun 25	Chardan Capital	Maintains	Buy → Buy	—	$0.75	$0.73	-2.7%	-2.7%	-2.7%	+6.3%	+1.1%	-1.7%
May 6	Chardan Capital	Maintains	Buy → Buy	—	$0.98	$0.98	+0.0%	-13.3%	+0.0%	-2.4%	-7.2%	+2.6%
May 5	Chardan Capital	Maintains	Buy → Buy	—	$1.01	$1.09	+7.9%	-3.0%	-13.3%	+0.0%	-2.4%	-7.2%
Jun 3	Chardan Capital	Maintains	Buy → Buy	—	$2.38	$2.45	+2.9%	+1.3%	+4.6%	-2.0%	-1.2%	-0.8%
Oct 7	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$80.00	$80.00	+0.0%	-12.5%	-13.1%	-18.8%	-1.6%	-2.9%
Nov 29	JMP Securities	Maintains	Outperform → Outperform	—	$330.00	$360.00	+9.1%	+28.8%	-11.8%	+1.3%	-3.9%	-9.6%
Jan 22	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$730.00	$885.00	+21.2%	+20.5%	-2.8%	+0.6%	-2.9%	-4.8%
Jan 21	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$725.00	$735.00	+1.4%	+0.7%	+20.5%	-2.8%	+0.6%	-2.9%
Jun 26	Alliance Global Partners	Maintains	Buy → Buy	—	$805.00	$1260.00	+56.5%	+33.5%	+14.4%	-9.8%	-6.3%	-5.8%

Institutional (13F) — Top 0 All ↗

No 13F holders found.

Mutual Funds / ETFs (N-PORT) — Top 1 All ↗

#	Fund	Shares	Value	Period
1	Guggenheim Active Allocation Fund	2	$6	Feb 2026

Data updated apr 25, 2026 2:44pm · Source: financialmodelingprep.com